Table 4.
Univariate and multivariable analysis of prognostic indicators on overall survival and cancer-specific survival for 331 stage III colorectal cancer patients
| Parameters | Overall survival | Cancer-specific survival | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariable analysis | Univariate analysis | Multivariable analysis | |||||
| HRc (95 % CId) | P value | HRc (95 % CId) | P value | HRc (95 % CId) | P value | HRc (95 % CId) | P value | |
| Age (years) | 1.157 (0.801 – 1.671) | 0.437 | 1.032 (0.607 – 1.754) | 0.909 | 1.157(0.801 – 1.670) | 0.438 | 1.032 (0.607 – 1.757) | 0.906 |
| ≥65 vs <65 (151/180) | ||||||||
| Gender | 1.347 (0.926 – 1.960) | 0.119 | 1.348 (0.795 – 1.356) | 0.227 | 1.336 (0.918 – 1.942) | 0.130 | 1.341 (0.827 – 2.176) | 0.235 |
| Male vs Female (183/148) | ||||||||
| Location | 1.828 (1.242 – 2.681) | 0.002* | 1.536 (0.939 – 2.513) | 0.087 | 1.842 (1.253 – 2.703) | 0.002* | 1.548 (0.946 – 2.532) | 0.082 |
| Right vs Left (80/251) | ||||||||
| Tumor size | 1.625 (1.120 – 2.359) | 0.011 | 1.557 (0.951 – 2.548) | 0.078 | 1.617 (1.114 – 2.345) | 0.011* | 1.544 (0.944 – 2.527) | 0.084 |
| ≥5 cm vs <5 cm (148/181) | ||||||||
| Tumor depth | 1.639 (0.799 – 3.363) | 0.178 | 0.935 (0.347 – 2.515) | 0.894 | 1.651 (0.805 – 3.388) | 0.171 | 0.937 (0.348 – 2.520) | 0.897 |
| T3 + T4 vs T1 + T2 (297/34) | ||||||||
| Histology | 2.171 (1.378 – 3.419) | 0.001* | 1.761 (0.969 – 3.201) | 0.063 | 2.185 (1.387 – 3.442) | 0.001* | 1.767 (0.972 – 3.210) | 0.062 |
| PD vs MD + WDa (45/277) | ||||||||
| Vascular invasion | 2.307 (1.565 – 3.399) | <0.001* | 1.784 (1.091 – 2.915) | 0.021* | 2.291 (1.555 – 3.376) | <0.001* | 1.777 (1.087 – 2.904) | 0.022* |
| Yes vs No (142/184) | ||||||||
| Perineural invasion | 1.866 (1.286 – 2.765) | 0.001* | 1.822 (1.112 – 2.986) | 0.017* | 1.880 (1.282 – 2.757) | 0.001* | 1.820 (1.111 – 2.983) | 0.017* |
| Yes vs No (142/183) | ||||||||
| Pre-op CEAb (ng/ml) | 1.925 (1.288 – 2.875) | 0.001* | 1.237 (0.697 – 2.195) | 0.468 | 1.945 (1.301 – 2.908) | 0.001* | 1.253 (0.706 – 2.224) | 0.441 |
| ≥5/ vs <5 (158/150) | ||||||||
| Post-op CEAb (ng/ml) | 3.253 (2.198 – 4.816) | <0.001* | 2.053 (1.187 – 3.550) | 0.010* | 3.285 (2.218 – 4.864) | <0.001* | 2.064 (1.193 – 3.571) | 0.010* |
| ≥5 vs <5 (81/234) | ||||||||
| Pre-op albumin (g/dl) | 1.480 (0.965 – 2.269) | 0.072 | 1.237 (0.740 – 2.067) | 0.417 | 1.474 (0.961 – 2.259) | 0.075 | 1.226 (0.734 – 2.046) | 0.437 |
| <3.5 vs ≥3.5 (85/185) | ||||||||
| Diabetes mellitus | 1.331 (0.888 – 1.996) | 0.166 | 1.103 (0.633 – 1.924) | 0.729 | 1.325 (0.884 –1.987) | 0.173 | 1.091 (0.626 – 1.903) | 0.758 |
| Yes vs No (80/251) | ||||||||
| Cardiac disease | 1.337 (0.926 – 1.931) | 0.121 | 0.796 (0.464 – 1.366) | 0.407 | 1.342 (0.929 – 1.938) | 0.117 | 0.799 (0.465 – 1.372) | 0.415 |
| Yes vs No (137/194) | ||||||||
| Renal disease | 4.151 (2.164 – 7.963) | <0.001* | 2.981 (1.089 – 8.157) | 0.033* | 4.165 (2.171 – 7.999) | <0.001* | 2.979 (1.088 – 8.159) | 0.034* |
| Yes vs No (13/318) | ||||||||
| Chemotherapy | 0.437 (0.257 – 0.742) | 0.002* | 1.061 (0.434 – 2.594) | 0.897 | 0.435 (0.256 – 0.738) | 0.002* | 1.078 (0.440 – 2.639) | 0.869 |
| Yes vs No (31/299) | ||||||||
aPD Poorly differentiated, MD Moderately differentiated, WD Well differentiated, b CEA Carcinoembryonic antigen, cHR Hazard ratio,
dConfidence interval
*Indicated P < 0.05